Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00

Stoke Therapeutics (NASDAQ:STOK) had its price objective increased by HC Wainwright from $35.00 to $50.00 in a research report sent to investors on Monday morning, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2027 earnings at ($2.08) EPS, FY2028 earnings at ($0.66) EPS and FY2029 earnings at $1.81 EPS.

Other research analysts also recently issued reports about the company. Chardan Capital upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Monday, December 8th. JPMorgan Chase & Co. increased their target price on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Needham & Company LLC boosted their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Finally, Wedbush raised their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Stoke Therapeutics currently has an average rating of “Buy” and a consensus price target of $34.78.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $32.86 on Monday. Stoke Therapeutics has a one year low of $5.35 and a one year high of $38.69. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of 49.04 and a beta of 1.14. The company’s 50-day moving average is $30.15 and its 200 day moving average is $21.21.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The company had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, research analysts predict that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 5,931 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $25.72, for a total transaction of $152,545.32. Following the transaction, the insider owned 7,195 shares of the company’s stock, valued at approximately $185,055.40. This represents a 45.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Md Kaye sold 42,461 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $25.09, for a total transaction of $1,065,346.49. Following the sale, the director directly owned 49,124 shares in the company, valued at $1,232,521.16. This represents a 46.36% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 182,166 shares of company stock valued at $5,136,957. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in STOK. Generali Investments Management Co LLC purchased a new stake in Stoke Therapeutics in the 3rd quarter valued at approximately $41,000. BNP Paribas Financial Markets boosted its stake in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the last quarter. AlphaQuest LLC acquired a new stake in shares of Stoke Therapeutics during the first quarter worth $72,000. Finally, US Bancorp DE increased its stake in shares of Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after acquiring an additional 11,108 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.